drugset / Trial / NCT06222892
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.
Timeline
- Start
- 2024-02-02
- Primary completion
- 2024-12-17
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camlipixant | Small molecule | 50 mg | Oral |
Indications
No indication recorded.